share_log

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

Benzinga ·  Jan 6 04:22  · Ratings

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $7 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment